FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma

Autor:	Jan Walewski, Ewa Paszkiewicz-Kozik, Janusz A. Siedlecki, Anna Fabisiewicz, MichaŁ Osowiecki
Rok vydání:	2011
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty Genotype medicine.medical_treatment Polymorphism Single Nucleotide Antibodies Monoclonal Murine-Derived Gene Frequency immune system diseases Prednisone hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Survival analysis Aged Aged 80 and over Chemotherapy biology business.industry Receptors IgG Remission Induction Hematology Middle Aged medicine.disease Survival Analysis Lymphoma Logistic Models Treatment Outcome Doxorubicin Vincristine Monoclonal biology.protein Female Rituximab Lymphoma Large B-Cell Diffuse Antibody business Diffuse large B-cell lymphoma medicine.drug
Zdroj:	Leukemia & Lymphoma. 52:1604-1606
ISSN:	1029-2403 1042-8194
DOI:	10.3109/10428194.2011.574760
Popis:	Rituximab in combination with chemotherapy significantly improves outcome compared to chemotherapy alone, and therefore it has become a new standard for the treatment of non-Hodgkin lymphomas (NHLs...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0145d6aadf533fcec5a0b5d57fec2b17 https://doi.org/10.3109/10428194.2011.574760 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.